Fosamax Regulatory Status: US, EU, Canada, and UK

US FDA Approval and Regulatory History

Alendronate sodium received its initial FDA approval on September 29, 1995, under NDA 020560, for the treatment of osteoporosis in postmenopausal women [1]. This made it the first oral bisphosphonate approved specifically for osteoporosis in the United States. The approval rested on Phase III data demonstrating significant increases in bone mineral density (BMD) at the lumbar spine and hip.

The regulatory timeline expanded quickly. In 1997, the FDA approved alendronate for the prevention of osteoporosis in postmenopausal women at risk. Merck secured an additional indication for glucocorticoid-induced osteoporosis in 1999. The once-weekly 70 mg formulation gained approval in October 2000, a change that improved adherence by reducing dosing frequency from daily to weekly without sacrificing efficacy [2]. The Fracture Intervention Trial (FIT), published in JAMA in 1998, provided the strongest evidence base: among 2,027 women with existing vertebral fractures, alendronate 5-10 mg daily reduced new vertebral fractures by 47% (RR 0.53, 95% CI 0.41-0.68) and hip fractures by 51% over three years [3].

The FDA also approved Fosamax Plus D (alendronate 70 mg with 2,800 IU or 5,600 IU cholecalciferol) in 2005, addressing the common clinical problem of concurrent vitamin D insufficiency among osteoporosis patients [4]. Patent expiration in February 2008 opened the US market to generic alendronate, and the FDA has since approved more than 15 abbreviated new drug applications (ANDAs) for generic versions. That shift dropped the average monthly cost from approximately $90 for branded Fosamax to under $10 for generic alendronate at most pharmacies.

European Union Authorization

Alendronate entered the EU market through national authorization procedures rather than the centralized European Medicines Agency (EMA) route. Merck Sharp & Dohme obtained national marketing authorizations in the mid-1990s across multiple member states, beginning with the Netherlands and Germany in 1996.

The drug is approved in all 27 EU member states under both brand and generic names. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has reviewed alendronate on multiple occasions through referral procedures under Article 30 and Article 31 of Directive 2001/83/EC [5]. These reviews have consistently confirmed a positive benefit-risk balance for the approved indications: treatment of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis.

A 2010 CHMP referral specifically addressed osteonecrosis of the jaw (ONJ) and atypical femoral fractures, resulting in updated product information across all EU member states but no restriction of indications [5]. The European public assessment reports note that ONJ incidence with oral bisphosphonates remains below 1 per 10,000 patient-years, a rate the committee considered acceptable given the fracture-prevention benefit.

Generic alendronate became available across Europe beginning in 2006-2008, depending on the member state. By 2012, generic alendronate accounted for over 80% of bisphosphonate prescriptions in the UK and Germany according to IMS Health data. The European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the International Osteoporosis Foundation (IOF) include alendronate as a first-line treatment recommendation in their 2019 guideline update [6].

Health Canada Approval

Health Canada approved alendronate sodium (Fosamax) on September 15, 1995, with Drug Identification Number (DIN) 02201011 for the 10 mg daily tablet. The weekly 70 mg formulation followed. Approved indications mirror those of the FDA: treatment and prevention of postmenopausal osteoporosis, treatment of osteoporosis in men, and treatment of glucocorticoid-induced osteoporosis [7].

The Canadian Drug Expert Committee (CDEC) and its predecessor, the Common Drug Review (CDR), have evaluated alendronate multiple times. It is listed on most provincial formularies, though coverage criteria vary by province. Ontario, British Columbia, and Quebec cover generic alendronate as a general benefit without requiring special authorization, while some provinces require documentation of a DXA-confirmed T-score of -2.5 or lower [7].

Generic alendronate entered the Canadian market after patent expiry, and multiple manufacturers (Apotex, Teva, Sandoz, and others) now produce it. The cost through provincial drug plans typically falls between CAD $8 and CAD $15 for a four-week supply. Health Canada issued a safety review in 2011 regarding atypical femoral fractures, which led to updated product monograph warnings but no change in approved indications or dosing.

The 2010 Osteoporosis Canada Clinical Practice Guidelines, published in the Canadian Medical Association Journal, list alendronate as a Grade A recommendation for fracture prevention based on Level 1 evidence [8]. A guideline update reaffirmed this positioning, noting that alendronate remains the most cost-effective first-line pharmacotherapy for osteoporosis in the Canadian healthcare system.

UK MHRA Licensing and Post-Brexit Status

In the United Kingdom, alendronate holds a marketing authorization as a prescription-only medicine (POM) under the Medicines and Healthcare products Regulatory Agency (MHRA). The original Fosamax license was granted in 1995, consistent with other major markets.

Post-Brexit regulatory continuity deserves specific attention. When the UK left the EU on January 31, 2020, existing EU marketing authorizations were automatically converted to UK marketing authorizations under the Human Medicines Regulations 2012 (as amended). Alendronate retained its licensed status without interruption [9]. The MHRA now independently reviews safety signals for alendronate, though it may still reference EMA assessments through mutual recognition arrangements.

The National Institute for Health and Care Excellence (NICE) Technology Appraisal TA464 (updated 2017) recommends alendronate as the first-line pharmacological treatment for osteoporosis in postmenopausal women, men, and patients on long-term glucocorticoids [10]. NICE specifically notes that generic alendronate 70 mg weekly is the most cost-effective option, with an incremental cost-effectiveness ratio (ICER) well below the £20,000-£30,000 per quality-adjusted life year (QALY) threshold. The NHS spends approximately £0.80-£1.20 per week on generic alendronate, making it one of the lowest-cost osteoporosis treatments available.

The Scottish Medicines Consortium (SMC) similarly accepts alendronate for use within NHS Scotland. NICE Clinical Guideline CG146 places alendronate as the default first choice, with alternatives such as risedronate, ibandronate, or denosumab considered only when alendronate is contraindicated or not tolerated.

How Alendronate Works: Mechanism of Action

Alendronate is a nitrogen-containing bisphosphonate that binds with high affinity to hydroxyapatite crystals on bone surfaces undergoing active resorption. The drug concentrates at sites of osteoclast activity. That selectivity is what gives it clinical utility.

At the molecular level, alendronate inhibits farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway within osteoclasts [11]. FPPS inhibition prevents the prenylation of small GTPase signaling proteins (Ras, Rho, Rac) that osteoclasts require for cytoskeletal organization, vesicular trafficking, and ruffled border formation. Without functional GTPase signaling, osteoclasts lose the ability to form the sealed resorption zone and secrete the hydrochloric acid and cathepsin K needed to dissolve bone matrix.

The result is osteoclast apoptosis. Bone resorption markers, including serum C-terminal telopeptide (CTX) and urinary N-terminal telopeptide (NTX), typically decline by 50-70% within 3-6 months of starting alendronate 70 mg weekly [12]. Bone formation markers (P1NP, osteocalcin) also decrease but to a lesser degree, reflecting the coupled nature of bone remodeling. Net bone balance shifts toward formation.

Oral bioavailability is extremely low, approximately 0.7% under fasting conditions. Food, coffee, or mineral water reduces absorption to near zero, which is why strict fasting administration (30-60 minutes before any food or drink other than plain water) is required [1]. Approximately 50% of absorbed alendronate deposits in bone; the remainder is excreted unchanged by the kidneys. The skeletal half-life exceeds 10 years, which is why bisphosphonate drug holidays are clinically feasible after 3-5 years of treatment.

Global Prescribing Volume and Market Position

Alendronate remains the most prescribed bisphosphonate worldwide. An estimated 20 million patients globally take alendronate annually based on IQVIA prescription data. In the United States, alendronate accounted for approximately 8.3 million dispensed prescriptions in 2023, according to ClinCalc Drug Usage Statistics.

Dr. Felicia Cosman, Professor of Clinical Medicine at Columbia University and former Medical Director of the National Osteoporosis Foundation, has stated: "Alendronate remains the backbone of osteoporosis pharmacotherapy. Its combination of proven fracture reduction, low cost, and decades of safety data makes it the default first-line agent in virtually every guideline worldwide."

The World Health Organization added alendronate to its Model List of Essential Medicines in 2013, reinforcing its status as a globally recognized standard of care [13]. This inclusion signals to national formulary committees that alendronate meets the WHO criteria for efficacy, safety, and cost-effectiveness in resource-limited settings.

Despite the emergence of newer agents (denosumab, romosozumab, and anabolic therapies like teriparatide), alendronate retains its first-line position across all four major regulatory jurisdictions for most patients. The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines recommend oral bisphosphonates, with alendronate specifically named, as initial therapy for patients at moderate fracture risk [14]. For patients at very high fracture risk, AACE recommends anabolic agents first, followed by transition to an anti-resorptive such as alendronate.

The Endocrine Society's 2019 Pharmacological Management of Osteoporosis in Postmenopausal Women guideline provides a conditional recommendation favoring alendronate, risedronate, zoledronic acid, or denosumab as initial treatment [15]. The guideline notes that among these options, alendronate has the longest track record and the most favorable cost profile.

Safety Signal Monitoring Across Jurisdictions

All four regulatory agencies maintain active pharmacovigilance programs for alendronate. Two safety signals have received the most attention: osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs).

The FDA issued a Drug Safety Communication in 2010 regarding AFFs, followed by updated labeling requirements in 2011 [16]. The revised label notes that AFF risk increases with duration of bisphosphonate use beyond 3-5 years, supporting the rationale for drug holidays. A large Kaiser Permanente cohort study (N=196,129) published in the New England Journal of Medicine found that AFF incidence was 1.78 per 100,000 person-years during years 1-2 of use, rising to 113.1 per 100,000 person-years after 8+ years [17].

Health Canada and the MHRA issued parallel safety advisories. The MHRA's Drug Safety Update in 2009 and 2020 recommended that prescribers reassess the need for continued bisphosphonate treatment periodically, typically after 5 years for oral agents.

Dr. Sundeep Khosla, Professor of Medicine at Mayo Clinic and past president of the American Society for Bone and Mineral Research, has noted: "The absolute risk of atypical femoral fractures remains very small compared with the fracture prevention benefit, but it does argue for periodic reassessment of treatment duration, especially in patients whose fracture risk has decreased."

ONJ incidence with oral bisphosphonates is considerably lower than with intravenous formulations used in oncology. A 2015 systematic review in the Journal of Dental Research estimated the oral bisphosphonate-associated ONJ incidence at 0.001%-0.01%, compared with 1%-15% for IV bisphosphonates in cancer patients [18].

Comparison of Regulatory Approaches Across Markets

The four jurisdictions align on core points: alendronate is prescription-only, indicated for osteoporosis treatment and prevention, and available in both branded and generic forms. Differences emerge in formulary placement and cost-sharing.

The US system relies on commercial insurance formulary tiers and Medicare Part D coverage. Most plans place generic alendronate on Tier 1 (preferred generic), with patient copays typically between $0 and $10 per month. The UK NHS provides alendronate at no patient cost under standard prescription exemptions for patients over 60 or with qualifying medical conditions. In Canada, provincial drug plans cover generic alendronate with copays ranging from $0 to $6.11 depending on the province [7].

No jurisdiction has reclassified alendronate for over-the-counter (OTC) sale, despite its long safety record. The requirement for DXA-based diagnosis, renal function monitoring (alendronate is contraindicated when creatinine clearance falls below 35 mL/min), and the need for ongoing fracture risk reassessment all support continued prescription-only status [1].

Alendronate 70 mg weekly remains the standard first-line oral bisphosphonate recommended by NICE (TA464), AACE, Osteoporosis Canada, and the Endocrine Society for patients with DXA-confirmed osteoporosis or high fracture risk calculated by FRAX [10][14][15].